Overcome Diverse Clinical Resistance Mechanisms with Emerging First- & Best-In-Class Combination & Monotherapies to Effectively Treat Patients with RAS-Driven Lung, Colorectal & Pancreatic Cancers
Welcome to the 6th Annual RAS-Targeted Drug Development Summit
Uniting Large Pharma, Innovative Biotech & Leading Academics to Defeat the Holy Grail Target in Precision Oncology
With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance. However, treating patients with RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the depth and durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.
Owing to this, the 6th Annual RAS-Targeted Drug Development Summit returns as the central hub dedicated to every aspect of discovery and development of RAS, from discovery and clinical development through to commercialization, equipping 200+ global RAS leaders with the means to create effective frontline RAS therapies for better patient outcomes.
What’s New for 2024?
Extensive technical content covering the latest advancements in identifying, validating and clinically progressing pan-RAS and selective inhibitors, vertical and parallel pathway targeting small molecules, cancer vaccines and cell therapies with improved potency and selectivity.
A new cohort of expert speakers and organizations presenting from the likes of Genfleet Therapeutics, Inspirna, Anocca, Bayer, Elicio Therapeutics, Frontier Medicines, Ranok Therapeutics, Ipsen Pharma and more.
Expert-led pre-conference workshops delving into the hottest aspirations of the precision oncology community, including the debate surrounding targeting wildtype RAS, how to overcome acquired resistance and how to inform combinations regimes in and before the clinic.
2024 Expert Speakers Include:
Geoff Oxnard
Vice President, Clinical Development, Global Head, Thoracic Cancer
Loxo Oncology at Lilly